Renalytixai plc, of New York, is collaborating with University Medical Center Groningen, the Netherlands, to evaluate Kidneyintelx on samples from more than 3,500 patients with type 2 diabetes to determine if Kidneyintelx can predict the best therapies for the treatment of diabetic kidney disease. Renalytixai plans to launch Kidneyintelx in its CLIA laboratory facilities in the U.S. in the second half of 2019.